DBV Technologies targets Q3 BLA filing for VIASKIN Peanut Patch
DBV Technologies has confirmed it expects to file a Biologics Licence Application with the US Food and Drug Administration for its VIASKIN Peanut Patch in children aged four through seven years during the third quarter of 2026, following iterative feedback from the regulator on the organisation and formatting of existing chemistry, manufacturing and controls and biostatistical datasets.
The Châtillon-based company said the FDA has not requested additional clinical data, a signal that investors typically read as positive momentum toward a standard review timeline. Chief executive Daniel Tassé said the company had made "meaningful progress" toward commercial readiness in the first half of the year, with investment flowing into medical affairs, sales, market access and pharmacovigilance functions in the United States.
Regulatory and clinical progress
The BLA timing represents a one-quarter slip from DBV's earlier second-quarter target, attributed entirely to formatting and mapping work on existing submissions rather than any new data requirement. The company said it has been in "detailed and iterative discussions" with the FDA throughout the period.
On the clinical side, DBV closed recruitment for the COMFORT Toddlers supplemental safety study, which evaluates the patch in children aged one through three years, and initiated the THRIVE study in infants aged six through twelve months. THRIVE is designed to assess whether three to four years of VIASKIN treatment can enable unrestricted dietary peanut consumption. Positive subgroup analyses from the Phase 3 VITESSE study were presented at both the American Academy of Allergy, Asthma and Immunology annual meeting and the European Academy of Allergy and Clinical Immunology congress in the first half.
Financial position and burn rate
DBV reported cash and cash equivalents of $174.9 million as of 30 June 2026, which the company said funds operations into the third quarter of 2027. The net loss widened to $98.0 million for the first half of 2026, against $69.0 million in the comparable period of 2025, as R&D expenses rose to $64.6 million and selling, general and administrative costs climbed by $20.7 million, reflecting pre-commercial infrastructure build-out. Net cash consumed by operating and investing activities reached $102.6 million in the half, nearly double the $54.0 million recorded in the same period last year.
Management noted that the runway estimate excludes costs from any in-licensing or acquisition activity and may be revised if regulatory timelines, clinical enrolment or foreign exchange conditions shift materially.
Market context and competitive landscape
Epicutaneous immunotherapy remains a small but increasingly competitive corner of the broader food allergy market. Oral immunotherapy for peanut allergy, represented by Aimmune's Palforzia, is the only currently approved desensitisation product for children in the United States, but the patch format is positioned by DBV as a lower-risk, non-invasive alternative that may suit younger age groups and those unable to tolerate oral dosing. If approved, VIASKIN Peanut would be the first epicutaneous immunotherapy on the market.
The epidemiological context has shifted modestly: DBV cited a recent assessment suggesting peanut allergy prevalence has remained statistically unchanged despite clinical guidelines encouraging earlier dietary introduction of allergenic foods, a finding that supports the durability of the addressable patient population and counters the hypothesis that earlier introduction would erode the market. Analysts and investors will be focused on the BLA acceptance date and any FDA correspondence following submission as the next key catalysts for the stock.